Free tool
FAERS Monitor: Visipaque 270
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020351 or its brand name (Visipaque 270, Iodixanol). Reports on generic versions are filed under their own applications.
Reports
3,613
Serious
3,321
92% of reports
Hospitalization
1,454
Death reported
273
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus478
- rash306
- erythema275
- dyspnoea257
- urticaria233
- nausea180
- hypotension158
- vomiting157
- acute kidney injury143
- contrast media allergy136
- anaphylactic reaction128
- rash maculo-papular120
- acute generalised exanthematous pustulosis105
- renal failure acute104
- swelling face102
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 49 |
| 2005 | 42 |
| 2006 | 69 |
| 2007 | 57 |
| 2008 | 73 |
| 2009 | 56 |
| 2010 | 82 |
| 2011 | 136 |
| 2012 | 135 |
| 2013 | 191 |
| 2014 | 282 |
| 2015 | 197 |
| 2016 | 220 |
| 2017 | 200 |
| 2018 | 169 |
| 2019 | 236 |
| 2020 | 170 |
| 2021 | 136 |
| 2022 | 106 |
| 2023 | 201 |
| 2024 | 239 |
| 2025 | 283 |
| 2026 | 284 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,546 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contrast media allergySignal | 136 | 466.9 | 393.3 | 58,114 |
| acute generalised exanthematous pustulosisSignal | 105 | 79.8 | 66.0 | 7,980 |
| rash maculo-papularSignal | 120 | 31.6 | 26.5 | 3,506 |
| renal failure acuteSignal | 104 | 14.3 | 11.8 | 1,273 |
| anaphylactic reactionSignal | 128 | 13.5 | 11.4 | 1,471 |
| swelling faceSignal | 102 | 9.1 | 7.5 | 732 |
| urticariaSignal | 233 | 8.1 | 7.2 | 1,454 |
| erythemaSignal | 275 | 7.8 | 7.0 | 1,637 |
| pruritusSignal | 478 | 7.2 | 6.7 | 2,613 |
| acute kidney injurySignal | 143 | 5.4 | 4.6 | 518 |
| hypotensionSignal | 158 | 4.6 | 3.9 | 444 |
| rashSignal | 306 | 4.1 | 3.7 | 725 |
| dyspnoeaSignal | 257 | 2.6 | 2.3 | 268 |
| vomiting | 157 | 1.9 | 1.7 | 73 |
| nausea | 180 | 1.3 | 1.1 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.